Teva delivered solid Q4 2025 results driven by its innovative portfolio, especially AUSTEDO and AJOVY, alongside a major development milestone payment. The company returned to profitability, with revenue and net income increasing significantly year-over-year.

Teva reported strong third-quarter 2025 results, with revenues reaching $4.5 billion, a 3% increase year-over-year. The growth was primarily fueled by its innovative portfolio, particularly AUSTEDO®, which saw a 38% increase in U.S. revenue. The company also raised its 2025 revenue outlook for AUSTEDO® and its non-GAAP EPS guidance, reflecting confidence in its 'Pivot to Growth' strategy and pipeline advancements.

Teva delivered its 10th consecutive quarter of year-over-year revenue growth in Q2 2025, with total revenues reaching $4.2 billion. The company's innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, significantly contributed to this growth, offsetting declines in generic products and COPAXONE. Teva also increased its 2025 revenue outlook for key innovative products and EPS, while reaffirming other financial guidance components.

Teva delivered $3.9 billion in revenue for Q1 2025, achieving its ninth consecutive quarter of growth. The company posted an adjusted EPS of $0.52 and generated $107 million in free cash flow, driven by innovative portfolio performance and effective cost management.

Teva's Q4 2024 revenues were $4,229 million, a decrease of 5% compared to Q4 2023. The decrease was mainly due to an upfront payment of $500 million received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by higher revenues from our innovative products AUSTEDO, UZEDY and AJOVY, from generic products in all our segments and from the sale of certain product rights.

Teva Pharmaceutical Industries Ltd. reported a strong third quarter of 2024, marking the seventh consecutive quarter of growth with global revenues reaching $4.3 billion, a 15% increase in local currency terms compared to the third quarter of 2023. The company's innovative portfolio and generics business drove this performance, leading to an increased 2024 financial outlook, including revenues, Adjusted EBITDA, and Non-GAAP EPS.

Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency, driven by generics and innovative businesses. AUSTEDO grew 32% in the U.S. The company is raising its financial guidance for 2024.

Teva Pharmaceutical Industries Ltd. reported a positive start to 2024, with global revenues of $3.8 billion, reflecting a 5% increase in local currency terms compared to Q1 2023. This growth was fueled by robust performance in the generics business across all regions and continued expansion of innovative brands AUSTEDO and AJOVY. The company reaffirmed its full-year 2024 financial outlook.

Teva Pharmaceutical Industries Ltd. reported a strong Q4 2023, with revenues of $4.5 billion, a 15% increase compared to Q4 2022. GAAP diluted earnings per share were $0.41, and non-GAAP diluted EPS was $1.00. The company's growth was driven by an upfront payment from an anti-TL1A asset collaboration, sale of product rights in Europe, and higher revenues from generic products and AUSTEDO.

Teva's Q3 2023 results showed a 7% increase in revenues to $3.9 billion, driven by the continued growth of AUSTEDO, AJOVY, and the global generics business. The company has raised its revenue outlook for 2023 for the second consecutive quarter.

Teva Pharmaceutical Industries reported a solid performance for Q2 2023, with revenues of $3.9 billion, a 4% increase in local currency terms, and a rise in non-GAAP gross margin. The company slightly increased its revenue guidance midpoint for the year and reaffirmed other guidance items, driven by growth from AUSTEDO and the launch of UZEDY.

Teva Pharmaceutical Industries Ltd. reported flat revenues of $3.661 billion for Q1 2023 compared to Q1 2022. However, in local currency terms, revenues increased by 4%. The company reported a GAAP loss per share of $0.18 and a non-GAAP diluted EPS of $0.40. Teva reaffirms its 2023 non-GAAP outlook.

Teva Pharmaceutical Industries Ltd. reported Q4 2022 revenues of $3.9 billion, a decrease of 5% in U.S. dollars or an increase of 1% in local currency terms compared to Q4 2021. GAAP diluted loss per share was $(1.10), while non-GAAP diluted EPS was $0.71. Cash flow generated from operating activities was $973 million, and free cash flow was $1,140 million.

Teva Pharmaceutical Industries Ltd. reported a decrease of 8% in revenues compared to the third quarter of 2021, with revenues of $3,595 million. GAAP diluted EPS was $0.05 and Non-GAAP diluted EPS was $0.59. The company generated $543 million in cash flow from operating activities and $685 million in free cash flow.

Teva reported Q2 2022 results with revenues of $3.8 billion. The company has reached an agreement in principle on a nationwide opioids settlement. The 2022 revenue outlook was revised due to foreign exchange headwinds and increased competition for COPAXONE, while reaffirming earnings and cash flow guidance.

Teva reported a decrease in revenues and a GAAP diluted loss per share, mainly due to lower revenues in North America and legal settlements. However, it saw gains in market share for AJOVY in the United States and Europe and reaffirmed its earnings and cash flow guidance.

Teva Pharmaceutical Industries Ltd. released its earnings report on February 9, 2022, announcing its financial results for the period ended December 31, 2021.

Teva Pharmaceutical Industries Ltd. reported flat revenues of $4,454 million for Q4 2020 compared to Q4 2019, with GAAP EPS at $0.14 and non-GAAP EPS at $0.68. The company met its 2020 financial guidance and saw minimal impact on its supply chain, R&D programs and product launches despite the COVID-19 pandemic.

Teva's Q3 2020 results showed resilience amidst the COVID-19 pandemic with revenues of $4.0 billion and non-GAAP diluted EPS of $0.58. The company launched digital inhalers and reduced net debt by more than $10 billion over three years.

Teva Pharmaceutical Industries Ltd. reported a decrease in revenues of 7% to $3.9 billion compared to the second quarter of 2019, mainly due to lower revenues from generics, OTC, and COPAXONE in all regions. GAAP diluted EPS was $0.13 and non-GAAP diluted EPS was $0.55. Free cash flow was $582 million. The company reaffirmed its full year 2020 business outlook.

Teva Pharmaceutical Industries Ltd. reported strong first quarter 2020 results, with revenues of $4.4 billion, GAAP diluted EPS of $0.06, non-GAAP diluted EPS of $0.76, and free cash flow of $551 million. The company reaffirmed its full-year 2020 business outlook.

Teva Pharmaceutical Industries Ltd. reported Q4 2019 results with revenues of $4.5 billion, a 1% increase compared to Q4 2018. GAAP earnings per share was $0.10 and non-GAAP EPS was $0.62. The company saw growth in sales of AUSTEDO, AJOVY, and certain respiratory products, which was partially offset by lower revenues from COPAXONE in North America.